Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents
Volume 6, Issue 11
Downloads and Tools
Pages 881 - 887http://dx.doi.org/10.4161/hv.6.11.12849
Authors: Christopher J. Gill, Roger Baxter, Alessandra Anemona, Giuseppe Ciavarro and Peter Dull View affiliations
The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one dose of Menveo® (MenACWY-CRM; Novartis) or Menactra® (MCV4) (sanofi pasteur). The proportion of subjects with hSBA titers ≥8 was significantly higher among recipients of MenACWY-CRM than MCV4 for serogroups A, W-135 and Y.